Ribostamicin
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| (1R,2R,3S,4R,6S)-4,6-diamino-3-hidroksi-2-(β-D-ribofuranoziloksi)cikloheksil 2,6-diamino-2,6-dideoksi-α-D-glukopiranozid | |||
| Klinički podaci | |||
| AHFS/Drugs.com | Internacionalno ime leka | ||
| Identifikatori | |||
| CAS broj | 53797-35-6 | ||
| ATC kod | J01GB10 | ||
| PubChem[1][2] | 5066 | ||
| UNII | 2Q5JOU7T53 
| ||
| ChEMBL[3] | CHEMBL1256830
| ||
| Hemijski podaci | |||
| Formula | C17H34N4O10 | ||
| Mol. masa | 454,47266 g/mol | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Sinonimi | (2R,3S,4R,5R,6R)-5-amino-2-(aminometil)-6[(1R,2R,3S,4R,6S)-4,6-diamino-2[(2S,3R,4S,5R)-3,4-dihidroksi-5-(hidroksimetil)oksolan-2-il]oksi3-hidroksicikloheksil]oksi}oksan-3,4-diol | ||
| Farmakoinformacioni podaci | |||
| Trudnoća | ? | ||
| Pravni status | |||
Ribostamicin je aminoglikozidni antibiotik.
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- Mandel GL, Bannett JE, Dolin R, ur. (2000). Principles and Practise of Infectious Diseases (5 izd.). Philadelphia, PA: Churchill Livingstone. DOI:10.1016/S1473-3099(10)70089-X. ISBN 0-443-07593-X.
